Articles & Video
REPORT: COVID-19 Response in Cell & Gene Therapy Manufacturing 2021
This exclusive report uncovers the major changes in the cell and gene therapy sector during the COVID-19 pandemic.
Ebook: The Future of the Cell and Gene Therapy Industry
What can we expect next from the cell and gene therapy sector? This ebook explores the potential paths ahead, from optimized CAR-T to automated bioprocessing.
COVID-19 has benefited investment in the cell and gene therapy sector, say 78% of industry professionals
We investigate how the COVID-19 pandemic has transformed business, finance and investment in cell and gene therapies.
Survey: Cell & Gene Therapy COVID-19 Response
What changes are happening in the cell and gene therapy sector as a result of the pandemic? Tell us your experience.
When to outsource manufacturing? Advice for cell and gene therapy developers
What scenarios could determine when is best to outsource manufacturing of cell and gene therapies to a CDMO?
Viral vectors have biggest limitations in vector manufacturing, according to industry survey
Exploring results of our industry survey, we identify the biggest pain points in vector manufacturing experienced by cell and gene therapy professionals.
Vector manufacturing for cell and gene therapies: how should current platforms be changed?
What do we need from vector manufacturing platforms to deliver commercial scale therapies? We look at responses from industry insiders.
Novel analytical strategies and tools for cell and gene therapies - WHITEPAPER
What analytical techniques can be applied to production of cell therapies, gene therapies and gene-edited cell-therapies? This whitepaper looks at the latest examples.
Insourcing vs outsourcing in cell and gene therapy manufacturing - WHITEPAPER
This whitepaper presents best practices for planning an outsourcing or insourcing strategy for manufacturing cell and gene therapies.
What is cell therapy?
What is cell therapy? Discover how cell therapies work, what diseases can be treated, how much they cost and the companies behind them.
Mesenchymal stem cells and understanding drug development processes
Sentien Biotech's VP of Operations, Chris Gemmiti, explores the current direction of mesenchymal stem cells and common hurdles in drug development.
What can reduce the cost of CAR-T therapy? - INDUSTRY VOICES
With such a high demand, what are the best available ways to lower the cost of CAR-T therapy? We ask three industry experts.
REPORT: Cell and Gene Therapy Analytics, Manufacturing and Supply Chain
Explore and download our latest data report on Cell and Gene Therapy Analytics, Manufacturing and Supply Chain, in partnership with Intertek.
How Kite Pharma built a robust CAR-T supply chain
How did Kite Pharma build its robust supply chain for CAR-T therapies without a precedent? We found out from Director of Global Supply Chain David Kim and Sr. Manager of Packaging Engineering, Craig Vermeyen.
Defining standards for cell and gene therapy products
This on-demand webinar with Sheng Lin-Gibson at National Institute of Standards & Technology summarizes the latest developments in standardizing cell and gene therapy manufacturing and commercialization.
Cell and gene therapies: The latest developments in viral and non-viral vector manufacturing
Discover the latest developments in viral and non-viral vector manufacturing for cell and gene therapies.
Sourcing and qualification of raw materials for producing cell and gene therapies - WHITEPAPER
This whitepaper examines the key factors to consider in the sourcing and qualification of raw materials for cell and gene therapies.
INDUSTRY VOICES: Tackling the downstream supply chain challenges of cell and gene therapies
How can specific challenges affecting the downstream supply chain for cell and gene therapies be addressed? These industry experts gave us their view.
Validating effectiveness and payment for single treatment gene therapies
As regulatory approvals of gene therapies increase, how can we assess their market value and identify payment structures?
Viral safety in cell and gene therapies with Thomas R. Kreil, VP at Takeda
Thomas R. Kreil, Vice President of Global Pathogen Safety at Takeda, discusses the new challenges to viral safety that cell and gene therapies present and how new technologies are helping overcome them.
Cell and Gene Therapies: Viral and Non-Viral Vector Manufacturing - WHITEPAPER
Download this exclusive whitepaper on viral and non-viral vector manufacturing in cell and gene therapies.